Equity Profile

GRFS

Grifols, S.A.

Health CareBiotechnology$5.4B

Feb28Mon

Pre-Earnings Brief

UpcomingQ3-2021After Close9:00 AM EST

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the production of plasma-derived medicines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Grifols is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the production of plasma-derived medicines. With a market cap of $5 billion, Grifols plays a crucial role in providing treatments for various medical conditions, making it significant in the health care sector.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

In the last quarter, Grifols reported an EPS of $0.24, which was below the expected $0.27, resulting in a 12.26% negative surprise. The stock reacted positively the following day, gaining 1.76%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Grifols are mixed as there are no analyst estimates available for this quarter. Investors are likely looking for signs of recovery after the last quarter's EPS miss.

Bull Case

If Grifols can show strong revenue growth and improved plasma collection, it could signal a turnaround, leading to increased investor confidence and stock price appreciation.

Bear Case

On the other hand, if the company fails to meet expectations again or provides weak guidance, it could lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current plasma collection volume and how does it compare to previous quarters?

This metric directly impacts Grifols' ability to produce its products and meet demand, making it crucial for assessing future revenue.

Will management provide guidance on revenue expectations for the next quarter?

Guidance can significantly influence investor sentiment and stock performance, especially after the recent EPS miss.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for recovery in plasma collection volumes, which could drive stronger-than-expected revenue growth this quarter.

Supporting Evidence

Options are pricing a 6.05% move, suggesting higher volatility than historical averages.

Grifols has historically shown resilience in revenue growth following prior misses.

Key Risk

If plasma collection volume exceeds previous levels, it could invalidate the cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on Grifols' ability to recover from last quarter's miss and provide clear indicators of future growth.

Bull Confirmed If

A plasma collection volume increase of over 10% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

A decline in plasma collection volume or lack of guidance could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±6.05%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may see limited movement as investors reassess.

Miss

Should Grifols miss expectations again, history suggests a potential decline of around 1.35%, which could further dampen investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on plasma collection volume and any changes in collection strategies.
2Management's guidance on revenue expectations for the next quarter.
3Any commentary on market demand for plasma-derived products.
4Insights into cost management and operational efficiencies.
5Discussion on competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb25

DHILReported

Diamond Hill Investment Group, Inc.

RecapView

Feb28

JLLReported

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the production of plasma-derived medicines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Grifols is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

In the last quarter, Grifols reported an EPS of $0.24, which was below the expected $0.27, resulting in a 12.26% negative surprise. The stock reacted positively the following day, gaining 1.76%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Grifols are mixed as there are no analyst estimates available for this quarter. Investors are likely looking for signs of recovery after the last quarter's EPS miss.

Bull Case

If Grifols can show strong revenue growth and improved plasma collection, it could signal a turnaround, leading to increased investor confidence and stock price appreciation.

Bear Case

On the other hand, if the company fails to meet expectations again or provides weak guidance, it could lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current plasma collection volume and how does it compare to previous quarters?

This metric directly impacts Grifols' ability to produce its products and meet demand, making it crucial for assessing future revenue.

Will management provide guidance on revenue expectations for the next quarter?

Guidance can significantly influence investor sentiment and stock performance, especially after the recent EPS miss.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for recovery in plasma collection volumes, which could drive stronger-than-expected revenue growth this quarter.

Supporting Evidence

Options are pricing a 6.05% move, suggesting higher volatility than historical averages.

Grifols has historically shown resilience in revenue growth following prior misses.

Key Risk

If plasma collection volume exceeds previous levels, it could invalidate the cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on Grifols' ability to recover from last quarter's miss and provide clear indicators of future growth.

Bull Confirmed If

A plasma collection volume increase of over 10% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

A decline in plasma collection volume or lack of guidance could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±6.05%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may see limited movement as investors reassess.

Miss

Should Grifols miss expectations again, history suggests a potential decline of around 1.35%, which could further dampen investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on plasma collection volume and any changes in collection strategies.
2Management's guidance on revenue expectations for the next quarter.
3Any commentary on market demand for plasma-derived products.
4Insights into cost management and operational efficiencies.
5Discussion on competitive positioning in the biotechnology sector.